Frequently Asked Questions

You can buy retatrutide in the UK directly from Alluvi Healthcare at buyalluvi.co.uk — the UK's dedicated supplier of research-grade retatrutide pens. We supply single units, bundles and wholesale 10-box orders with fast discreet UK delivery. All products are supplied for research and development purposes only. Our official WhatsApp for orders is +44 7394 241184.

Ordering is simple and fully online — there are no in-store or walk-in purchases:

• Browse our products page and select your compound and quantity
• Use the order builder to add items, then click "Order via WhatsApp" — your order details are pre-filled automatically
• Our team confirms availability and sends payment instructions within minutes
• Once payment is confirmed, your order is dispatched with full COA documentation

You can also email us at support@buyalluvi.co.uk with your order details.

We accept multiple payment methods for your convenience. Payment instructions are sent after your order is confirmed via WhatsApp or email. We do not accept cash or in-person payments under any circumstances. Contact us via WhatsApp for full details on accepted payment methods for your specific order.

No. Alluvi Healthcare operates exclusively online. We do not accept walk-in customers, in-person collections, or cash payments under any circumstances. All orders must be placed via WhatsApp or email only. Anyone claiming to represent Alluvi Healthcare in person or on social media is not affiliated with us.

Alluvi Healthcare offers wholesale and bulk research peptide supply across all our product lines. Our standard bulk tiers start at 3-pack and 10-pack pricing — visible on our products page. For larger enterprise orders (50, 100, 500+ units) for qualified UK research institutions, contact us via WhatsApp at +44 7394 241184 for a custom wholesale quote.

The Alluvi Retatrutide 40mg Pen price in the UK starts at £195 per box (single unit). Bulk pricing: 3 boxes at £510 (save £75), and 10-box wholesale orders from £1,500 (save £450). All prices include UK delivery and a full Janoshik Certificate of Analysis. View full pricing →

Retatrutide 20mg starts at £125 per box. The 3-box bundle is £320 (save £55). The Retatrutide 20mg x2 Bundle (two pens in one box) is £169.99. All include UK delivery and full COA documentation.

Alluvi Healthcare's Tirzepatide 40mg starts at £115 per box, and Tirzepatide 20mg at £75. Mounjaro (brand-name tirzepatide) costs £1,050–£1,400/month on private prescription in the UK. Our research-grade tirzepatide uses the same active molecule for a fraction of the cost. Please note: all Alluvi products are supplied for research and development purposes only.

Yes — Alluvi Healthcare offers significant bulk discounts across all product lines:

• 3-pack: ~13% saving vs single unit price
• 10-pack: ~23% saving vs single unit price
• Enterprise tiers (50–500+ units): Custom pricing — contact us via WhatsApp

All bulk orders include full COA documentation, cold chain logistics, and dedicated account support.

Retatrutide (LY3437943) is a next-generation peptide that acts as a triple agonist of GLP-1, GIP, and glucagon receptors simultaneously. Unlike single-pathway GLP-1 agonists such as semaglutide (Ozempic), retatrutide's triple-receptor mechanism delivers significantly superior metabolic modulation in research settings. Phase 2 clinical trials published in the New England Journal of Medicine showed an average of 22.5% body weight reduction at 48 weeks — more than any other GLP-1 class compound tested to date. All Alluvi retatrutide is supplied for research and development purposes only.

• Retatrutide: Triple agonist (GLP-1 + GIP + Glucagon) — 22.5% average weight reduction in Phase 2 trials
• Semaglutide: Single GLP-1 agonist — ~15% weight reduction in STEP trials

Retatrutide's tri-agonist mechanism makes it particularly valuable for research investigating multi-pathway metabolic modulation, energy expenditure, and synergistic receptor interactions. Semaglutide is better suited for focused GLP-1 single-pathway mechanism studies. For research purposes, retatrutide represents the next generation beyond both semaglutide and tirzepatide.

Tirzepatide (the active molecule in Mounjaro) is a dual agonist targeting GLP-1 and GIP receptors — showing ~22% weight reduction. Retatrutide adds a third mechanism — glucagon receptor agonism — which increases resting energy expenditure significantly. In head-to-head research comparisons, retatrutide demonstrates superior fat oxidation and metabolic modulation due to this additional pathway. Both compounds are available as research-grade peptides from Alluvi Healthcare.

NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in all living cells, central to cellular energy metabolism and DNA repair. Research applications include cellular energy metabolism, brain cellular repair, anti-aging mechanisms, and mitochondrial function studies. Alluvi's NAD+ 1,000mg pen delivers 2 pre-filled doses of 100mg each for controlled research applications. R&D use only.

• BPC-157 & TB-500 40mg: A combined recovery and repair blend. BPC-157 (Body Protection Compound) and TB-500 (Thymosin Beta-4) are studied for tissue repair, wound healing and regeneration research applications.
• Glow GHK-Cu 70mg: A blend of BPC-157 10mg, TB-500 10mg and GHK-Cu (copper peptide) 50mg. GHK-Cu is studied for skin cellular repair, hair follicle research and anti-aging mechanisms.

All supplied for in vitro laboratory research only. Not for human or veterinary use.

Yes. Every batch of Alluvi peptides is independently tested by Janoshik Analytical to ≥98% purity via HPLC (High Performance Liquid Chromatography) and confirmed by Mass Spectrometry for molecular identity. A full Certificate of Analysis (COA), batch documentation, and MSDS are included with every UK order. You can verify batch results directly at the Janoshik verification portal ↗

Every Alluvi Healthcare order includes:

• Certificate of Analysis (COA) — HPLC purity data, mass spectrometry confirmation, batch number
• MSDS (Material Safety Data Sheet) — safe handling, storage and disposal information
• Batch traceability documentation — full chain of custody from synthesis to dispatch
• Reconstitution and storage guidelines

All documentation is provided digitally. Physical copies available on request for wholesale orders.

• Unused pens: Refrigerate at 2–8°C. Do not freeze.
• In transit: All Alluvi orders are dispatched in temperature-controlled cold-chain packaging to maintain compound integrity.
• After first use: Keep refrigerated and use within the timeframe specified in the product documentation.
• Avoid: Direct sunlight, heat above 8°C, repeated freeze-thaw cycles.

Shelf life is 24–36 months when stored properly in original sealed packaging. Specific stability data is provided in the batch COA.

UK orders are processed and dispatched within 3–5 business days. Express 1–2 day delivery is available for £12.99. All orders ship in temperature-controlled, discreet outer packaging with real-time tracking provided. We dispatch from our London and Northern Ireland facilities — whichever carries available stock for fastest dispatch to your location.

Yes — all orders are dispatched in plain, discreet outer packaging with no Alluvi Healthcare branding visible externally. The outer box carries only the necessary courier labels. Internal packaging maintains cold chain integrity with temperature-control materials. Your privacy is fully protected on every order.

Alluvi Healthcare operates from two UK locations — London (primary hub, serving England and Wales) and Northern Ireland (secondary hub, serving Northern Ireland and Scotland). Orders are dispatched from whichever facility has stock available to ensure the fastest possible delivery to your postcode.

Real-time tracking is provided on every order. Once your order is dispatched, you will receive a tracking number via WhatsApp or email. All shipments are sent via tracked courier services. If you have any concerns about your delivery, contact us via WhatsApp at +44 7394 241184 for immediate assistance.

Retatrutide is not approved by the MHRA for human therapeutic use and is currently in Phase 3 clinical trials. It is legal to supply and possess as a research chemical for laboratory R&D purposes in the UK. Alluvi Healthcare supplies retatrutide strictly for in vitro laboratory research and development under R&D use conditions. Buyers are responsible for ensuring compliance with all applicable UK regulations governing research peptides in their jurisdiction.

Based on current Phase 3 trial timelines (TRIUMPH programme), retatrutide is not expected to receive MHRA approval until late 2026–2027 at the earliest. NHS availability would follow 12–24 months after MHRA approval (requiring NICE assessment). When approved, brand-name retatrutide will likely be priced at £800–£1,500+/month. Research-grade retatrutide from Alluvi Healthcare is available now for qualified R&D applications.

Legitimate purchases from Alluvi Healthcare will always:

• Come through our official website buyalluvi.co.uk or WhatsApp +44 7394 241184
• Include a Janoshik COA you can verify independently at the Janoshik portal
• Never ask for extra "insurance" or "delivery fees" after payment
• Never ask you to send money to a personal bank account with no order reference

If you are unsure about a seller claiming to be Alluvi, contact us directly via WhatsApp to verify before sending any payment.

Alluvi retatrutide pens are pre-filled and ready to use — no mixing or reconstitution required. Each 40mg pen contains 4 doses of 10mg. General research guidance:

• Remove pen from refrigerator 15–30 minutes before use to reach room temperature
• Inspect — solution should be clear and colourless
• Prime the pen on first use by dialling a small priming dose
• Administer subcutaneously per your research protocol
• Return to refrigerator immediately after use

Full instructions are included with every order. For detailed research protocol guidance, contact our technical team via WhatsApp. All products are for research use only — not for human consumption.

• Retatrutide 20mg pen: 4 doses of 5mg. Ideal for titration research, dose-response studies, and protocols starting at lower concentrations. £125/box.
• Retatrutide 40mg pen: 4 doses of 10mg. Higher-dose formulation for advanced metabolic research protocols. £195/box.

Both are pre-filled, ready-to-use research devices with identical documentation standards. The 20mg x2 bundle (£169.99) provides two 20mg pens for extended lower-dose research programmes.

Yes — our knowledgeable team provides technical support on reconstitution guidance, storage optimisation, and protocol questions via WhatsApp. Real specialists, not a chatbot. Contact us at +44 7394 241184 or email support@buyalluvi.co.uk. We typically respond within 30 minutes during business hours.